Abiopharma

🔍 Wagner Paul A. (Executive)

Company: Forte Biosciences, Inc. (FBRX)

Report Date: 2026-01-12

Detailed Transactions and Holdings:

• Acquired 270,000 shares of Stock Option (right to buy) at $29.66 per share (Derivative)
  Date: 2026-01-12 | Code: A | Expires: 2036-01-12 | equity_swap_involved: 0 | shares_owned_after: 270,000.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 180,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-12 | Code: A | equity_swap_involved: 0 | shares_owned_after: 180,000.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026.
• F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
• F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one fourth (1/4th) of the total RSUs subject to the award shall vest annually on the anniversary of Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026.
• REMARKS: CEO, Secretary and Chair of the Board